Annovis fully enrolls Phase 3 AD trial with 850 patients; Q2 net loss $0.40/share

Annovis Bio, Inc.

Pivotal Phase 3 AD trial fully enrolled with 850 patients, exceeding original target of 760; topline symptomatic data expected Q1 2027.
PD OLE study enrolled 266 of 500 patients; full enrollment projected Q4 2026; 26 US sites activated.
Q2 2026 net loss $0.40/share vs $0.32 in Q2 2025; R&D spend $12.0M vs $5.2M YoY.
Cash $18.7M at June 30, 2026 vs $19.5M at Dec 31, 2025; 42.6M shares outstanding.
Cheng Fang, Ph.D. promoted to Chief Scientific Officer; AD OLE study to initiate October 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.